Details of the Drug Reposition

General Information of This Drug (ID: DM3U9BY)

Drug Name
RO-5126766   DM3U9BY
Synonyms VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Non-small-cell lung cancer DISI0V1B 2C25 Phase 2 [1]
Ovarian cancer DISZJHAP 2C73 Phase 2 [1]
------------------------------------------------------------------------------------
1 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Solid tumour/cancer DISZR48F 2A00-2F9Z Phase 1 [2]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT04625270) A Study of VS-6766 v. VS-6766 + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation. U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT02407509) Phase I Trial of RO5126766. U.S. National Institutes of Health.